CompletedPhase 3

Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients

Indonesia122 participantsStarted 2011-11

Plain-language summary

This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy (NACT)

Who can participate

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * IIIB/C and IV stage of breast cancer * received neoadjuvant hormonal therapy or neoadjuvant chemotherapy * had first and second biopsy (surgery) within 6 months Exclusion Criteria: * had mastectomy before treatment * pregnant * disagree to enter the study * had been given hormonal therapy or chemotherapy before study * had contra-indication of SOB for pre-menopausal patients

What they're measuring

Overall survival

Timeframe: time from the date of pathological diagnosis until death from any cause and until minimum sample sizes are met and an average 3 years

Trial details

NCT IDNCT02995772

SponsorDharmais National Cancer Center Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2018-11

View on ClinicalTrials.gov More Breast Cancer trials